Sacituzumab Govitecan-hziy

Gosartumomab (trade name Trodelvy [2]) is indicated for use in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least 2 systemic therapies (at least 1 of which was for metastatic disease).
It is indicated for use in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least 2 systemic therapies (at least 1 of which was for metastatic disease). [1]